A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease

2009110 citationsJournal Articlehybrid Open Access

Authors

Charlotte Keywood · Addex Therapeutics (Switzerland)

Melanie Wakefield · Addex Therapeutics (Switzerland)

Abstract

The mGluR5 negative allosteric modulator ADX10059 reduced acid reflux which was associated with improvement in clinical symptoms in patients with GORD. ADX10059 appears to have a potential role in the clinical management of GORD.

Topics & Keywords

Gastroesophageal reflux and treatments Helicobacter pylori-related gastroenterology studies Eosinophilic Esophagitis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gut

Volume 58, Issue 9, pp. 1192-1199

DOI: 10.1136/gut.2008.162040

Field-Weighted Citation Impact: 13.54